Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
Date:8/4/2009

al Cancer (CRC): Presented new progression-free survival (PFS), disease control and neurotoxicity data from a randomized, controlled Phase 2 trial of picoplatin for the first-line treatment of metastatic CRC at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The results continue to support picoplatin as a neuropathy-sparing alternative to oxaliplatin with similar anti-tumor activity as assessed by PFS and disease control measured by tumor response rate. New data derived by three independent assessments indicated a statistically significant reduction in neurotoxicities with the use of picoplatin in the FOLPI regimen compared with oxaliplatin in the FOLFOX regimen (p<0.0019).

  • Castration-Resistant Prostate Cancer (CRPC): Presented new progression-free survival data from a Phase 2 clinical trial of picoplatin for the first-line treatment of patients with metastatic CRPC at the 2009 ASCO Annual Meeting. The updated efficacy and safety data demonstrated that picoplatin in combination with docetaxel and prednisone is active as first-line therapy for metastatic CRPC as demonstrated by several endpoints, including reductions in prostate specific antigen (PSA) levels, disease control as measured by tumor response, and PFS. Results also continue to show that picoplatin can be safely administered every three weeks for up to 10 cycles concurrently with full doses of docetaxel and prednisone, the standard treatment for CRPC. In addition, no neurotoxicity was observed in these patients.

Corporate Developments

  • Announced the appointment of Gary A. Lyons to the Board of Directors in July 2009. His appointment increases the number of directors to 10. Mr. Lyons has been and will continue to serve as a consultant to Poniard on matters of corporate and business development as the Company moves forward with its commercialization and par
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
2. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
3. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
4. Poniard Pharmaceuticals Files Shelf Registration
5. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
6. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
9. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
10. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
11. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 The Market Element LLC, ... strategic alliance with Designing Gig LLC to provide website ... , “Forging this alliance with Designing Gig represents ... can extend a comprehensive, end-to-end, digital solution for our ... execution,” said Chuck Miller, president of The Market Element. ...
(Date:3/26/2015)... Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... a three-year, broad research collaboration for rare diseases. The ... develop novel therapies to treat rare diseases with ... commercialization capabilities with Cincinnati Children,s research expertise. As ...
(Date:3/26/2015)... PAREXEL International Corporation (Nasdaq: ... organization , announced today that the Company ... all of the business assets of privately-owned Quantum ... specialized pharmacovigilance services, based in Chandigarh, India.  ... monitoring, and prevention of adverse effects with ...
(Date:3/26/2015)... "In America," the popular news television program that airs ... by legendary film actor James Earl Jones, has announced that ... segment. , Botany is commonly described as the scientific ... a bit more complicated than that. Scientists and other professionals ... from the smallest bacteria known to man to the largest ...
Breaking Biology Technology:The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... Mass., Jan. 9, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: ... discovery and development of drugs for the treatment of ... hepatitis C virus (HCV) development pipeline. ... of a phase I clinical trial of the Company,s ...
... 9, 2012 , Collaboration to create ... to active TB, enabling early treatment and disease outbreak prevention ... infectious disease portfolio with development of DNA-/RNA-based test that complements ... , New assay will use whole blood transcription profiling ...
... FRANCISCO, Jan. 7, 2012 Sutro Biopharma, a biopharmaceutical ... pharmaceutical properties, today announced that it has appointed James ... its newly formed scientific advisory board (SAB).  Prof. Wells ... "We have brought together two leading scientific experts in ...
Cached Biology Technology:Idenix Reports Advancement of HCV Development Pipeline 2Idenix Reports Advancement of HCV Development Pipeline 3Idenix Reports Advancement of HCV Development Pipeline 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 2QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 3QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 5QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 6QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 7Sutro Announces Newly Formed Scientific Advisory Board 2Sutro Announces Newly Formed Scientific Advisory Board 3
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year history ... Hammacher Schlemmer introduces The Eye Scanning Password Authenticator ... granting access to secure websites or sensitive data. ... travelers at international borders, the device has a small ... points of the iris, converting them into an encrypted ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... After every meal, the body must prevent the immune ... researchers report the identity of a nutrient "floodgate" that ... Their findings appear in the May 4, 2007 issue ... , The researchers found that animals lacking a protein ...
... body appears to control whether certain medications, such as ... or in inhalers for asthma, lose their effectiveness over ... the body that controls many functions, including the contraction ... conducted by Duke University Medical Center and Howard Hughes ...
... diabetic patients of the superbug MRSA - by treating ... and his team used green bottle fly larvae to ... with MRSA and found all but one were cured ... than the 28-week duration for the conventional treatment. ...
Cached Biology News:Keeping the immune system from starting a 'food fight' 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3Maggots rid patients of MRSA 2
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: cap, ...
... Pre-tested for optimal ... support the growth of ... for methylcellulose colony-forming assays ... hematopoietic cells. Not suitable ...
... RAW 264. 7 cells were cultured in DMEM ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
Biology Products: